Update to the Latin American Thoracic Society (ALAT) Recommendations on Infectious Exacerbation of COPD

ERS consensus statement. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). A consensus statement of the European Respiratory Society (ERS).

Eur Respir J, 8 (1995), pp. 1398-1420

Medline

[7]

British Thoracic Society.

BTS guidelines for the management of chronic obstructive pulmonary disease.

Thorax, 52 (1997), pp. 4-28

[8]

JA Barberà, G Peces-Barba, AGN Agustí, JL Izquierdo, E Monsó, T Montemayor, et al.

Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica.

Arch Bronconeumol, 37 (2001), pp. 297-316

Medline

[9]

MS Balter, RH Hyland, DE Low, PM Renzi, AC Braude, PJ Cole, et al.

Recommendations on the management of chronic bronchitis. A practical guide for Canadian physicians.

Can Med Ass J, 151 (1994), pp. 7-23

[10]

RA Pauwels, AS Buist, PMA Calverley, CR Jenkins, SS Hurd.

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary.

Am J Respir Crit Care Med, 163 (2001), pp. 1256-1276

http://dx.doi.org/10.1164/ajrccm.163.5.2101039 | Medline

[11]

NR Anthonisen, J Manfreda, CPW Warren, ES Hershfield, GKM Harding, NA Nelson.

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.

Ann Intern Med, 106 (1987), pp. 196-204

Medline

[12]

DM Mannino, C Brown, GA Giovino.

Obstructive lung disease deaths in the United States from 1979 through 1993. An analysis using multiple-cause mortality data.

Am J Respir Crit Care Med, 156 (1997), pp. 814-818

http://dx.doi.org/10.1164/ajrccm.156.3.9702026 | Medline

[13]

V Sobradillo, M Miravitlles, R Gabriel, CA Jiménez-Ruiz, C Villasante, JF Masa, et al.

Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study.

Chest, 118 (2000), pp. 981-989

Medline

[14]

AMB Menezes, CG Victoria, M Rigatto.

Prevalence and risk factors for chronic bronchitis in Pelotas, RS, Brazil: a population-based study.

Thorax, 49 (1994), pp. 1217-1221

Medline

[15]

R Sansores, JR Pérez-Padilla.

Enfermedad pulmonar obstructiva crónica. Un problema mundial, un enfoque en México, Piensa Ed., (1997),

[16]

INEGI, SSA/DGEI.

Estadísticas vitales. Mortalidad, Estados Unidos Mexicanos, 1997, INEGI, SSA/DGEI, (1998),

[17]

D Maldonado, F Bolívar, A Caballero, A Casas, J Roa, C Salgado.

Sociedad Colombiana de Neumología y Cirugía de Tórax. Recomendaciones para el diagnóstico y manejo del paciente con enfermedad pulmonar obstructiva crónica (EPOC).

Rev Colombe Neumol, 9 (1997), pp. 1-39

[18]

Report number 12681-CH. Chile. The adult health policy change. Human resources operation division. Country department. Latin America and the Caribbean Region. Document of the World Bank. 10 November, 1994.

[19]

J Christopher, L Murray, A López.

Global health statistics.

Harvard University Press,

[20]

Secretaría de Salud.

Dirección General de Epidemiología. Instituto Mexicano de Psiquiatría. Encuesta Nacional de las Adicciones, tabaco, SSA, (1993),

[21]

Department of Health and Human Services. Centers for Diseases Control. Smoking and health in the Americas. USA. Atlanta: DHHS publication number CDC 92-8420, 1992.

[22]

Farías Alburquerque C, Vega Huaman R, Gamboa Aboado R, Pinillos Ashton L, Diouff MA. Plan nacional para prevención y control del tabaquismo en el Perú 2001-2005. Comisión Multisectorial Permanente de Lucha Antitabáquica-COLAT Perú. Ministerio de Salud. Organización Panamericana de Salud. Lima, 2001.

[23]

L Arango, J Luna, G Martínez, M Flores.

Tabaquismo en Guatemala.

Boletín OPS, 2 (1990), pp. 6-9

[24]

EA Carlini, JC Galduróz, AR Noto, SA Nappo.

I levantamento domiciliar sobre o uso de drogas psicotrópicas no Brasil, CLR Balieiro Editores Ltda, (2002),

[25]

B Ostro, JM Sánchez, C Aranda, G Eskaland.

Air pollution and mortality: results from a study in Santiago, Chile.

J Exp Environ Epidemiol, 6 (1996), pp. 97-114

[26]

DP Tashkin, R Detals, M Simmonds, H Liu, AH Coulson, J Sayre, et al.

The UCLA population studies of chronic obstructive respiratory diseases. Impact of air pollution and smoking on annual change in forced expiratory volume in one second.

Am J Respir Crit Care Med, 149 (1994), pp. 1209-1217

http://dx.doi.org/10.1164/ajrccm.149.5.8173761 | Medline

[27]

R Pérez-Padilla, J Regalado, S Vadel, P Pare, R Chapela, R Samons, et al.

Exposure to biomass smoke and chronic airway diseases in Mexican women.

Am J Respir Crit Care Med, 154 (1996), pp. 701-706

http://dx.doi.org/10.1164/ajrccm.154.3.8810608 | Medline

[28]

RJ Dennis, D Maldonado, S Norman, E Baena, G Martínez.

Wood smoke exposure and risk for chronic obstructive airways disease among women.

Chest, 109 (1996), pp. 115-119

Medline

[29]

J Luna, L Arango.

Bronquitis crónica secundaria a la exposición al humo de leña. Archivos Unidad Pulmonar. Hospital Roosevelt.

Revista de Medicina Interna de Guatemala, 3 (1996), pp. 16-20

[30]

DJ Hendrick.

Occupation and chronic obstructive pulmonary disease (COPD).

Thorax, 51 (1996), pp. 947-955

Medline

[31]

SO Shaheen, DJP Barker, AW Shiell, FJ Crocker, GA Wield, ST Holgate.

The relationship between pneumonia in early childhood and impaired lung function in late adult life.

Am J Respir Crit Care Med, 149 (1994), pp. 616-619

http://dx.doi.org/10.1164/ajrccm.149.3.8118627 | Medline

[32]

P Hodgins, PK Henneberger, M-L Wang, EL Petsonk.

Bronchial responsiveness and five-year FEV1 decline: a study in miners and nonminers.

Am J Respir Crit Care Med, 157 (1998), pp. 1390-1396

http://dx.doi.org/10.1164/ajrccm.157.5.9701123 | Medline

[33]

AJ Sandford, TD Weir, PD Paré.

Genetic risk factors for chronic obstructive pulmonary disease.

Eur Respir J, 10 (1997), pp. 1380-1391

[34]

M Miravitlles, R Vidal, Gracia J de.

Enfisema por déficit de alfa-1-antitripsina. Situación actual y nuevas perspectivas para el tratamiento.

Arch Bronconeumol, 28 (1992), pp. 296-302

[35]

M Miravitlles, C Mayordomo, M Artés, L Sánchez-Agudo, F Nicolau, JL Segú, on behalf of the EOLO Group.

Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice.

Respir Med, 93 (1999), pp. 173-179

Medline

[36]

E Monsó, J Ruiz, A Rosell, J Monterola, J Fiz, J Morera, et al.

Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush.

Am J Respir Crit Care Med, 152 (1995), pp. 1316-1320

http://dx.doi.org/10.1164/ajrccm.152.4.7551388 | Medline

[37]

S Sethi, N Evans, BJB Grant, T Murphy.

New strains of bacteria and exacerbations of chronic obstructive pulmonary disease.

N Engl J Med, 347 (2002), pp. 465-471

http://dx.doi.org/10.1056/NEJMoa012561 | Medline

[38]

J Eller, A Ede, T Schaberg, MS Niederman, H Mauch, H Lode.

Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function.

Chest, 113 (1998), pp. 1542-1548

Medline

[39]

M Miravitlles, C Espinosa, E Fernández-Laso, JA Martos, JA Maldonado, M Gallego, Study Group of Bacterial Infection in COPD.

Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD.

Chest, 116 (1999), pp. 40-46

Medline

[40]

D Lieberman, D Lieberman, O Shmarkov, Y Gelfer, M Ben-Yaakov, Z Lazarovich, et al.

Serological evidence of Legionella species infection in acute exacerbation of COPD.

Eur Respir J, 19 (2002), pp. 392-397

Medline

[41]

N Mogulkoc, S Karakurt, B Isalska, U Bayindir, T Celikel, V Korten, et al.

Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection.

Am J Respir Crit Care Med, 160 (1999), pp. 349-353

http://dx.doi.org/10.1164/ajrccm.160.1.9809041 | Medline

[42]

SS Richter, AB Brueggemann, HK Huynh, PR Rhomberg, EM Wingert, R Flamm, et al.

A 1997-1998 national surveillance study: Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US institutions.

Intern J Antimicrob Agents, 13 (1999), pp. 99-107

[43]

M Guzmán-Blanco, JM Casellas, HS Sader.

Bacterial resistance to antimicrobial agents in Latin America. The giant is awakening.

Infect Dis Clin North Am, 14 (2000), pp. 67-81

Medline

[44]

T Soler, L Salamanca, G Arbo, E Molina.

Susceptibilidad in vitro de cepas de Streptococcus pneumoniae aisladas de infecciones de las vías aéreas inferiores en el Instituto Nacional del Tórax (INT).

Rev Med Chil, 130 (2002), pp. 304-308

Medline

[45]

D Felmingham, RN Gruneberg.

The Alexander Project 19961997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections.

J Antimicrob Chemother, 45 (2000), pp. 191-203

Medline

[46]

R Wise, D Honeybourne.

Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract.

Eur Respir J, 14 (1999), pp. 221-229

Medline

[47]

D Felmingham.

Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT Global Surveillance Study.

J Infect, 44 (2002), pp. 3-10

Medline

[48]

H López, H Sader, C Amábile, W Pedreira, JL Muñoz Bellido, JA García Rodríguez, y Grupo MSP-LA.

Actividad in vitro de moxifloxacino frente a patógenos respiratorios en Iberoamérica.

Rev Esp Quimioterap, 15 (2002), pp. 325-334

[49]

RA Stockley, C O'Brien, A Pye, SL Hill.

Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD.

Chest, 117 (2000), pp. 1638-1645

Medline

[50]

PR Murray, JA Washington.

Microscopic and bacteriologic analysis of expectorated sputum.

Mayo Clin Proc, 50 (1975), pp. 339-344

Medline

[51]

SG Adams, J Melo, M Luther, A Anzueto.

Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD.

Chest, 117 (2000), pp. 1345-1352

Medline

[52]

JT MacFarlane, A Colville, A Guion, RM MacFarlane, DH Rose.

Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community.

Lancet, 341 (1993), pp. 511-514

Medline

[53]

P Ball, JM Harris, D Lowson, G Tillotson, R Wilson.

Acute infective exacerbations of chronic bronchitis.

Q J Med, 88 (1995), pp. 61-68

[54]

GJ Huchon, G Gialdroni-Grassi, P Léophonte, F Manresa, T Schaberg, M Woodhead.

Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey.

Eur Respir J, 9 (1996), pp. 1590-1595

Medline

[55]

NA Dewan, S Rafique, B Kanwar, H Satpathy, K Ryschon, GS Tillotson, et al.

Acute exacerbation of COPD. Factors associated with poor treatment outcome.

Chest, 117 (2000), pp. 662-671

Medline

[56]

M Miravitlles, C Murio, T Guerrero, on behalf of the DAFNE Study Group.

Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. A prospective multicenter study in the community.

Eur Respir J, 17 (2001), pp. 928-933

Medline

[57]

M Miravitlles.

El fracaso en el tratamiento de las agudizaciones de la enfermedad pulmonar obstructiva crónica. Factores de riesgo e importancia clínica.

Med Clin (Barc), 119 (2002), pp. 304-314

[58]

M Miravitlles, C Murio, T Guerrero, R Gisbert, on behalf of the DAFNE study group.

Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD.

Chest, 121 (2002), pp. 1449-1455

Medline

[59]

M Miravitlles, C Murio, T Guerrero, R Gisbert, on behalf of the DAFNE study group.

Costs of chronic bronchitis and COPD. A one year follow-up study.

Chest, 123 (2003), pp. 784-791

Medline

[60]

GH Murata, MS Gorby, CO Kapsner, TW Chick, AK Halperin.

A multivariate model for predicting hospital admissions for patients with decompensated chronic obstructive pulmonary disease.

Arch Intern Med, 152 (1992), pp. 82-86

Medline

[61]

R Antonelli Incalzi, L Fuso, M de Rosa, F Forastiere, E Rapiti, B Nardecchia, et al.

Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease.

Eur Respir J, 10 (1997), pp. 2794-2800

Medline

[62]

E Prescott, P Lange, J Vestbo.

Chronic mucus hypersecretion in COPD and death from pulmonary infection.

Eur Respir J, 8 (1995), pp. 1333-1338

Medline

[63]

C Landbo, E Prescott, P Lange, J Vestbo, TP Almidal.

Prognostic value of nutritional status in chronic obstructive pulmonary disease.

Am J Respir Crit Care Med, 160 (1999), pp. 1856-1861

http://dx.doi.org/10.1164/ajrccm.160.6.9902115 | Medline

[64]

R Kessler, M Faller, G Fourgaut, B Mennecier, E Weitzenblum.

Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease.

Am J Respir Crit Care Med, 159 (1999), pp. 158-164

http://dx.doi.org/10.1164/ajrccm.159.1.9803117 | Medline

[65]

M Miravitlles, T Guerrero, C Mayordomo, L Sánchez-Agudo, F Nicolau, JL Segú, on behalf of the EOLO Study Group.

Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis.

Respiration, 67 (2000), pp. 495-501

http://dx.doi.org/67462 | Medline

[66]

AF Connors Jr, NV Dawson, C Thomas, FE Harrel Jr, N Desbiens, WJ Fulkerson, et al.

Outcomes following acute exacerbation of severe chronic obstructive pulmonary disease.

Am J Respir Crit Care Med, 154 (1996), pp. 959-967

http://dx.doi.org/10.1164/ajrccm.154.4.8887592 | Medline

[67]

R Wilson, R Kubin, I Ballin, KM Deppermann, HP Bassaris, P Leophonte, et al.

Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.

J Antimicrob Chemother, 44 (1999), pp. 501-513

Medline

[68]

S Chodosh, A Schreurs, G Siami, HW Barkman, A Anzueto, M Shan, et al.

The efficacy of oral ciprofloxacin vs. clarithromycin for the treatment of acute bacterial exacerbations of chronic bronchitis.

Clin Infect Dis, 27 (1998), pp. 730-738

Medline

[69]

N Soler, S Ewig, A Torres, X Filella, J González, A Xaubet.

Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease.

Eur Respir J, 14 (1999), pp. 1015-1022

Medline

[70]

SW Crooks, DL Bayley, SL Hill, RA Stockley.

Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4.

Eur Respir J, 15 (2000), pp. 274-280

Medline

[71]

A Bhowmik, TAR Seemungal, RJ Sapsford, JA Wedzicha.

Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations.

Thorax, 55 (2000), pp. 114-120

Medline

[72]

P Bresser, TA Out, L van Alphen, HM Jansen, R Lutter.

Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic Haemophilus influenzae airway infection.

Am J Respir Crit Care Med, 162 (2000), pp. 947-952

http://dx.doi.org/10.1164/ajrccm.162.3.9908103 | Medline

[73]

A Anzueto, JA Rizzo, RF Grosman.

The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis.

Clin Infect Dis, 28 (1999), pp. 1344-1345

http://dx.doi.org/10.1086/517802 | Medline

[74]

IS Patel, TAR Seemungal, M Wilks, SJ Lloyd-Owen, GC Donaldson, JA Wedzicha.

Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations.

Thorax, 57 (2002), pp. 759-764

Medline

[75]

GC Donaldson, TAR Seemungal, A Bhowmik, JA Wedzicha.

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.

Thorax, 57 (2002), pp. 847-852

Medline

[76]

TMA Wilkinson, IS Patel, M Wilks, GC Donaldson, JA Wedzicha.

Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease.

Am J Respir Crit Care Med, 167 (2003), pp. 1090-1095

http://dx.doi.org/10.1164/rccm.200210-1179OC | Medline

[77]

RA Stockley.

Role of bacteria in the pathogenesis and progression of acute and chronic lung infection.

Thorax, 53 (1998), pp. 58-62

Medline

[78]

M Miravitlles.

Exacerbations of chronic obstructive pulmonary disease: when are bacteria important?.

Eur Respir J, 20 (2002), pp. 9-19

[79]

DE Niewoehner, ML Erbland, RH Deupree, D Collins, NJ Gros, RW Light, et al.

Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease.

N Engl J Med, 340 (1999), pp. 1941-1947

http://dx.doi.org/10.1056/NEJM199906243402502 | Medline

[80]

L Davies, RM Angus, PMA Calverley.

Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial.

Lancet, 354 (1999), pp. 456-460

Medline

[81]

AT Evans, S Husain, L Durairaj, LS Sadowski, M Charles-Damte, Y Wang.

Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial.

Lancet, 359 (2002), pp. 1648-1654

http://dx.doi.org/10.1016/S0140-6736(02)08597-5 | Medline

[82]

L Allegra, C Grassi, E Grossi, E Pozzi, F Blasi, D Frigerio, et al.

Ruolo degli antibiotici nel trattamento delle riacutizzazioni della bronchite cronica: risultati di uno studio italiano multicentrico.

Ital J Chest Dis, 45 (1991), pp. 138-148

[83]

S Saint, S Bent, E Vittinghoff, D Grady.

Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis.

JAMA, 273 (1995), pp. 957-960

Medline

[84]

WA Craig.

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Clin Infect Dis, 26 (1998), pp. 1-12

Medline

[85]

M Miravitlles, C Murio, T Guerrero, JL Segú.

Tratamiento de la bronquitis crónica y la EPOC en atención primaria.

Arch Bronconeumol, 35 (1999), pp. 173-178

Medline

[86]

S Kesten, KR Chapman.

Physician perceptions and management of COPD.

Chest, 104 (1993), pp. 254-258

Medline

[87]

M Miravitlles.

Moxifloxacin: an antibiotic designed for use in the community.

Eur Respir Rev, 10 (2000), pp. 161-169

[88]

I Odenholt, E Lowdin, O Cards.

Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens.

Antimicrob Agents Chemother, 45 (2001), pp. 23-29

http://dx.doi.org/10.1128/AAC.45.1.23-29.2001 | Medline

[89]

M Aubier, PM Aldons, A Leak, DD McKeith, B Leroy, M Rangaraju, et al.

Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis.

Respir Med, 96 (2002), pp. 862-871

Medline

[90]

N Soler, A Torres, S Ewig, J González, R Celis, M El-Ebiary, et al.

Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation.

Am J Respir Crit Care Med, 157 (1998), pp. 1498-1505

http://dx.doi.org/10.1164/ajrccm.157.5.9711044 | Medline

[91]

KL Nichol, L Baken, A Nelson.

Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease.

Ann Intern Med, 130 (1999), pp. 397-403

Medline

[92]

Centers for Disease Control and Prevention.

Prevention of pneumococcal disease. Recommendations of the Advisory Committee of Immunization Practices (ACIP).

MMWR Morb Mortal Wkly Rep, 46 (1997), pp. 1-24

Medline

These recommendations were made possible by the unrestricted support of Bayer and Aventis.

*

Members of the ALAT Work Group Coordinators: J.M. Luna (Guatemala) and J.R. Jardim (Brazil). Work Group Members: H. López, C.M. Luna, J.A. Mazzei, and D. Stamboulian (Argentina); J.C. Abreu de Oliveira and J. Pereira (Brazil); A. Díaz, C. Lisboa, and F. Saldías (Chile); D. Maldonado and C. Torres (Colombia); S. Martínez Selmo (Dominican Republic); M. Miravitlles, F. Rodríguez de Castro, and A. Torres (Spain); A. Anzueto and J. Ramírez (USA); M. Díaz, R. Pérez Padilla, A. Ramírez, and R. Sansores (Mexico); I. Carrasco (Panama); A. Matsuno (Peru).

Indexed in:

Follow us:

Subscribe:

Indexed in:

Follow us:

Subscribe:

Subscribe to our newsletter